These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 37894366)

  • 81. Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.
    Buder A; Hochmair MJ; Schwab S; Bundalo T; Schenk P; Errhalt P; Mikes RE; Absenger G; Patocka K; Baumgartner B; Setinek U; Burghuber OC; Prosch H; Pirker R; Filipits M
    J Thorac Oncol; 2018 Jun; 13(6):821-830. PubMed ID: 29505901
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Plasma
    Wang X; Liu Y; Meng Z; Wu Y; Wang S; Jin G; Qin Y; Wang F; Wang J; Zhou H; Su X; Fu X; Wang X; Shi X; Wen Z; Jia X; Qin Q; Gao Y; Guo W; Lu S
    Ann Transl Med; 2021 Apr; 9(8):635. PubMed ID: 33987333
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study).
    Chihara Y; Yamada T; Uchino J; Tamiya N; Kaneko Y; Kishimoto J; Takayama K
    Transl Lung Cancer Res; 2019 Dec; 8(6):1086-1090. PubMed ID: 32010586
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT).
    Addeo A; Hochmair M; Janzic U; Dudnik E; Charpidou A; Płużański A; Ciuleanu T; Donev IS; Elbaz J; Aarøe J; Ott R; Peled N
    Ther Adv Med Oncol; 2021; 13():17588359211059874. PubMed ID: 35173817
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Sequential use of EGFR-tyrosine kinase inhibitors based upon EGFR mutation evolution achieves long-term control in a non-small cell lung cancer patient: a case report.
    Jiang Y; Zhang J; Jiang X; Cheng L; Liao X; Li Y; Zhang M; Chen R; Yin T
    Ann Palliat Med; 2021 Jun; 10(6):7051-7056. PubMed ID: 33548986
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y; Hao X; Xing P; Hu X; Wang Y; Li T; Zhang J; Xu Z; Li J
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2427-2433. PubMed ID: 32385709
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
    Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
    Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Mechanisms of resistance to osimertinib.
    Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
    J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study.
    Shi Y; Wu S; Wang K; Cang S; Yao W; Fan Y; Wu L; Huang M; Li X; Pan Y; Yang Z; Zhu B; Chen G; Shi J; Sun M; Fang J; Wang L; Chen Z; Liu C; Li J; Liu J; Sun S; Zhao Y; Guo Y; Meng Z; Liu Z; Han Z; Lu H; Ma R; Hu S; Zhao G; Liu Z; Xie C; Zhong D; Zhao H; Yu H; Zhang L; Bi M; Yi S; Guo S; Yi T; Li W; Lin Y; Shu Y; Chen Z; Guo Z; Greco M; Wang T; Shen H
    J Thorac Oncol; 2022 Nov; 17(11):1306-1317. PubMed ID: 36049654
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
    Saad N; Poudel A; Basnet A; Gajra A
    Onco Targets Ther; 2017; 10():1757-1766. PubMed ID: 28367058
    [TBL] [Abstract][Full Text] [Related]  

  • 92. An Observational Study of Acquired
    Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
    Front Oncol; 2020; 10():1481. PubMed ID: 33014788
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression.
    Inomata M; Minatoyama S; Takata N; Hayashi K; Hirai T; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Tobe K
    Mol Clin Oncol; 2024 Jun; 20(6):43. PubMed ID: 38756869
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced
    Zhang D; Liu X; Shen F; Zhao D; Shi Y; Zhang H; Liu J; Gao X; Chen M; Zhao J; Zhong W; Gao J; He M; Liu Y; Yang X; Qin J; Tang Y; Mu X; Gu Y; Zhang S; Chen X; Pang L; Meng Q; Guo Y; Zhang Y; Li W; Xing P; Cheng Y; Xin T; Li Q; Li Y; Chen J; Gao F; Jin B; Rossi A; Adachi H; Guerrera F; Husain H; Xu Y; Wang M
    Transl Lung Cancer Res; 2023 Nov; 12(11):2229-2244. PubMed ID: 38090527
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B).
    Yang JC; Ohe Y; Chiu CH; Ou X; Cantarini M; Jänne PA; Hartmaier RJ; Ahn MJ
    Clin Cancer Res; 2022 Jun; ():OF1-OF10. PubMed ID: 35735998
    [TBL] [Abstract][Full Text] [Related]  

  • 96. A Novel
    Sun Y; Pei L; Luo N; Chen D; Meng L
    Onco Targets Ther; 2020; 13():11177-11181. PubMed ID: 33173309
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Next-Generation
    Sullivan I; Planchard D
    Front Med (Lausanne); 2016; 3():76. PubMed ID: 28149837
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve
    Le X; Patel JD; Shum E; Baik C; Sanborn RE; Shu CA; Kim C; Fidler MJ; Hall R; Elamin YY; Tu J; Blumenschein G; Zhang J; Gibbons D; Gay C; Mohindra NA; Chae Y; Boumber Y; Sabari J; Santana-Davila R; Rogosin S; Herzberg B; Creelan B; Pellini B; Tanvetyanon T; Heeke S; Hernandez M; Gray JE; Saltos A; Heymach JV
    J Clin Oncol; 2024 Oct; ():JCO2400533. PubMed ID: 39378386
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy.
    Hsu PC; Chang JW; Chiu LC; Yang CT; Kuo SC; Fang YF; Wu CE
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39317868
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study.
    Cuppens K; Lodewyckx L; Demedts I; Decoster L; Colinet B; Deschepper K; Janssens A; Galdermans D; Pieters T;
    Drugs Real World Outcomes; 2021 Jun; 8(2):141-152. PubMed ID: 33710523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.